GeneDx Holdings Corp. Revenue 2019–2025
GeneDx Holdings Corp. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- GeneDx Holdings Corp. revenue for the quarter ending March 31, 2026 was 102.3 M, a 17.38% increase year-over-year.
- GeneDx Holdings Corp. revenue for the twelve months ending March 31, 2026 was 408.8 M, a 55.37% increase year-over-year.
- GeneDx Holdings Corp. annual revenue for 2025 was 427.5 M, a 39.97% increase from 2024.
- GeneDx Holdings Corp. annual revenue for 2024 was 305.4 M, a 50.79% increase from 2023.
- GeneDx Holdings Corp. annual revenue for 2023 was 202.6 M, a 13.69% decrease from 2022.
- GeneDx Holdings Corp. annual revenue for 2022 was 234.7 M.
GeneDx Holdings Corp. (WGS) — Frequently Asked Questions
GeneDx Holdings Corp. (WGS) is a publicly traded US company. It has a market capitalization of $1.56B. In fiscal 2025 it reported revenue of $428M and net income of -$21M. Explore WGS's stock price, financial statements, earnings history, margins and key ratios below.
What is GeneDx Holdings Corp.'s market cap?
GeneDx Holdings Corp. (WGS) has a market capitalization of $1.56B.
What is the WGS stock price?
WGS trades at $54.32 (-3.57% on the day).
How much revenue does GeneDx Holdings Corp. make?
GeneDx Holdings Corp. reported revenue of $428M in fiscal 2025.
Is WGS profitable?
In fiscal 2025, GeneDx Holdings Corp. reported net income of -$21M.